Think this one could have the potetial to be really big... Check out the company info and post any thoughts you have... has massive potential

HYLEO
Not exactly 25p. At current 46p think they have a bit further to go

It looks more like it is heading for single figures.

It is already 25p today as I predicted...and I certainly agree with Haystack in his case as RENE has no potential viable product in the short to medium term.
IT IS HEADING FOR 15P next stop. SELL!

interesting reading from other thread:

smokin_jokin - 4 Apr'07 - 09:55 - 3546 of 3547

End of tax year lots of people dumping stock to get under CGT threshold, they will be buying back in next week again though...these should tick up hopefully. Love to buy more at this price, but now fully invested.

News soon.

water30 - 4 Apr'07 - 10:17 - 3547 of 3547

Was a former holder of RENE a few months back. I have bought back in because I believe it is massively undervalued but most importantly, I like the potential here. Will look to add more if the price drops again.

:-) enjoy

More...

TOPINFO - 3 Apr'07 - 15:59 - 3543 of 3547
I wouldnt go that far but its cheap now thats for sure. Remember broker target is 106p at least.!!!

It's not even all-or-nothing.
First we have to overcome the US Authorities, just to start the trial
then we have to wait, hope the trials are positive
and that US Authorities don't put it on Hold again!
and then the Trials have to be positive . . . . and PAID for - that's not cheap!
Then we have to wait for Approval, a commercial deal etc.

Of course by the time we're half-way through the sp will be doubled - but that still means many hurdles before we get there........just overcomming the US-Hold appears to be taxing Execs....I wonder why? . . . . This is nearly 1-year on. . . .

If in the meanwhile they need more Dosh - there will be a Placing; so your investment will be diluted, so anything you paid will have cost, maybe 10% more (effectively)....Grr.

Widow and Orphan status springs to mind! - no not the patients who are delayed treatment by the FDA ( see RNS and sp fall today - Yikes!),
No, - I mean the remaining family who "might" have been spared widowhood, at least for a few more weeks, months, etc.

Of course FDA has a responsibility towards trial patients - but to delay Trials twice smacks of Nimbyism, but that's just a sly view - if they fall any further, I might buy for the "future" - the present can't get much worse - or can it?

Perhaps we should allow more foreigners into Britain provided they take part in Trials - they wouldn't mind, would they?

Attention, Attention....

These boys are shifting, look out

Nice rise yesterday, how far is it likely to go. Current sp of 13.75 mid is mcap of 21million approx. Was 12million 2 days ago.

yeah, I have my stop loss set at 13p at the moment..... I think they could be good to 15p maybe, but time will tell.

The Government had passed a new bill unrestricting the use of certain stem cell techniques

Very surprised that this has not been flagged up in the last few days.
Share price rise has been terrific on the news from America that the FDA has authorised stem cell research to go ahead in human tests, and it has also been ok`d by UK authorities to go ahead with their stroke stem cells in human tests.
They are still talking to the FDA, and if this turns positive then the price at the moment will be extremely cheap.

Alert serviceSite mapSearchHome
Home News & events NewsNews article
ReNeuron gains UK regulatory approval to start ground-breaking clinical trial with stem cell therapy for stroke . 19/01/09
Guildford, UK, 19 January 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a first-in-man clinical trial for the treatment of patients who have been left disabled by an ischaemic stroke, the most common form of the condition. Stroke is the third largest cause of death and the single largest cause of adult disability in the developed world.

In this ground-breaking Phase I trial, the first of its kind using expanded neural stem cells, stroke patients will be treated with ReNeuron's ReN001 stem cell therapy at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board. The Principal Investigator for the trial is Dr. Keith Muir, Senior Lecturer in Neurology at the University of Glasgow. MHRA approval for the trial has been given subject to provision of data both from an ongoing pre-clinical study and from the long term follow-up of trial participants. Following successful completion of the ethics approval process which is currently underway for the trial, patient recruitment is expected to commence in the second quarter of this year.

The trial is designed primarily to test the safety profile of ReN001 in ischaemic stroke patients at a range of cell doses, but a number of efficacy measures will also be evaluated over the course of the trial. The ReN001 cells will be administered by direct injection into the affected region of the brain in a straightforward surgical procedure. Importantly, the nature of the procedure and the characteristics of the ReN001 cells mean that the patients will not require immunosuppression following treatment, thus eliminating the safety risks typically associated with immunosuppression regimens. Patients in the trial will be monitored for one year, with longer term follow-up procedures in place thereafter.

Dr. Keith Muir said:

"Stem cell treatment offers the potential to repair brain tissue lost as a result of stroke. We are very excited at the opportunity to undertake this, the first clinical trial involving neural stem cell therapy in stroke. At this stage, we are primarily seeking to establish the safety and feasibility of this form of treatment, and if successful, we hope that it will lead on to larger studies looking at the effects of the treatment on patient recovery".


Michael Hunt, Chief Executive Officer of ReNeuron, said:

"This regulatory approval marks the first step in the process of testing the safety and potency of our lead ReN001 stroke therapy at a clinical level. It is the most important milestone in ReNeuron's history thus far and also represents a significant development in the wider field as regards the translation of exciting stem cell science into clinical stage therapies. In many ways, ReNeuron has set the regulatory pathway in the UK for cell therapy trials of this type, and we are delighted to have been given the opportunity to move ReN001 into its clinical phase on home territory in the UK"


Enquiries:

ReNeuron

IMHO, A lot of hot air, for this Co has had a far greater Punter Interest ( and sp) quite some while ago. In that event they muffed it, destroying many shareholder beliefs that this was the way forward.
So not everyone believes this is the start of something BIG....rather it's the same old hooey, relaunched in another guise.
Today, the sp shows that 4x as many punters want "out" as are willing to pay "spike prices" - - - Oh deary.

New article, Click HERE

FUND-Raising at 3p/Share

Oh deary, for retail shareholders - this will mean DILUTION, no wonder the sp has fallen so quickly today!

-and the way I read it most of this 3million is already spoken-for by way of repaying Loans . . . . . can someone else explain otherwise?

No need to explain hangon - you're a PI, and you've been shafted

Don't worry though - no need to lose any sleep as the institutions and the board have all been looked after.

This is a dummy company...bail out and don't invest in it.

Couldn't agree more - the board, its advisors et al are init for themselves, and themselves only.

What posters on other boards are assuming is that this fund raising will be enough - that in itself is highly debatable, but the board has certainly shown how it would like to spread the rewards if and when they do come - certainly ain't gonna be for the PI

Maybe one to tuck away in the bottom draw with this news, if the research comes good could be worth a bit.,.

Thursday we'll have annual results from ReNeuron , the stem technology researcher. The firm is not in profit yet, but it has high hopes for its ReN001 stem cell therapy for the treatment of the effects of a stroke. It is currently in clinical development.